New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - doxycycline hydrochloride 57mg (as docyclycine hyclate = doxycycline 50mg);   - tablet - 50 mg - active: doxycycline hydrochloride 57mg (as docyclycine hyclate = doxycycline 50mg)   excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry white y-1r-7000b

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - hydrocortisone 1%;  ;   - lotion - 1 % - active: hydrocortisone 1%     excipient: carbomer cetyl alcohol glycerol lanolin liquid paraffin methyl hydroxybenzoate polysorbate 60 propyl hydroxybenzoate purified water sorbitan stearate trolamine

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - letrozole 2.5mg;   - film coated tablet - 2.5 mg - active: letrozole 2.5mg   excipient: colloidal silicon dioxide iron oxide yellow lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1-7000 sodium starch glycolate

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cyproterone acetate 2mg;  ; ethinylestradiol 0.035mg;   - film coated tablet - active: cyproterone acetate 2mg   ethinylestradiol 0.035mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry buff oy-3690 opadry white y-1r-7000b opaglos white 6000 povidone purified water quinoline yellow sucrose lactose monohydrate magnesium stearate microcrystalline cellulose - estelle-35 and estelle-35 ed are indicated for the treatment of androgen dependent diseases in women, such as acne (where oral antibiotics or local treatment alone has not been successful), especially pronounced forms and those which are accompanied by seborrhoea or by inflammation or formation of nodes (acne papulopustulosa, acne nodulocystica), androgenic alopecia, mild forms of hirsutism. estelle-35 and estelle-35 ed are also indicated for oral contraception in women requiring treatment for these androgen-dependent diseases; it is not recommended in women solely for contraception. estelle-35 and estelle-35 ed are also indicated for treating the symptoms of polycystic ovary syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - flucloxacillin sodium monohydrate 1 g;   - powder for injection - 1 g - active: flucloxacillin sodium monohydrate 1 g   - latest regulatory activity

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - flucloxacillin sodium monohydrate 250mg;   - powder for injection - 250 mg - active: flucloxacillin sodium monohydrate 250mg  

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - flucloxacillin sodium monohydrate 500mg;   - powder for injection - 500 mg - active: flucloxacillin sodium monohydrate 500mg  

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: ammonia solution butyl alcohol colloidal silicon dioxide ethanol gelatin   iron oxide black isopropyl alcohol lactose monohydrate magnesium stearate maize starch patent blue v   potassium hydroxide propylene glycol purified water   shellac sodium laurilsulfate titanium dioxide   water - ozole 150 mg capsule, given orally, is indicated for vaginal candidiasis.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fluconazole 200mg - capsule - 200 mg - active: fluconazole 200mg excipient: ammonia solution butyl alcohol colloidal silicon dioxide erythrosine ethanol gelatin   iron oxide black isopropyl alcohol lactose monohydrate magnesium stearate maize starch patent blue v potassium hydroxide propylene glycol purified water   shellac sodium laurilsulfate titanium dioxide   water - ozole is indicated for the treatment of the following conditions: 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. ozole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseninated candidasis and other forms of invasive candidal infection, including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytoxic chemotherapy, radiotherapy or bone marrow transplant. 6. ozole 50 mg and 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fluconazole 50mg - capsule - 50 mg - active: fluconazole 50mg excipient: ammonia solution butyl alcohol colloidal silicon dioxide ethanol gelatin   iron oxide black isopropyl alcohol lactose monohydrate magnesium stearate maize starch patent blue v potassium hydroxide propylene glycol purified water   shellac sodium laurilsulfate titanium dioxide   water - ozole is indicated for the treatment of the following conditions: 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. ozole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseninated candidasis and other forms of invasive candidal infection, including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytoxic chemotherapy, radiotherapy or bone marrow transplant. 6. ozole 50 mg and 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.